Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) EBT Margin (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed EBT Margin for 6 consecutive years, with 5226.32% as the latest value for Q4 2020.

  • For Q4 2020, EBT Margin fell 148816.0% year-over-year to 5226.32%; the TTM value through Dec 2020 reached 4708.17%, down 91523.0%, while the annual FY2025 figure was 145.26%, 117898.0% up from the prior year.
  • EBT Margin hit 5226.32% in Q4 2020 for Syndax Pharmaceuticals, roughly flat from 5238.26% in the prior quarter.
  • Across five years, EBT Margin topped out at 1594.89% in Q4 2017 and bottomed at 5238.26% in Q3 2020.
  • Average EBT Margin over 5 years is 4162.45%, with a median of 4309.0% recorded in 2017.
  • Year-over-year, EBT Margin soared 3175379bps in 2016 and then plummeted -349274bps in 2018.
  • Syndax Pharmaceuticals' EBT Margin stood at 3564.92% in 2016, then skyrocketed by 55bps to 1594.89% in 2017, then plummeted by -219bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then crashed by -40bps to 5226.32% in 2020.
  • According to Business Quant data, EBT Margin over the past three periods came in at 5226.32%, 5238.26%, and 4382.59% for Q4 2020, Q3 2020, and Q2 2020 respectively.